Research programme: farnesoid-X-activated receptor agonists - Metacrine

Drug Profile

Research programme: farnesoid-X-activated receptor agonists - Metacrine

Alternative Names: M 480; MET 409

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Metacrine
  • Class Antifibrotics; Small molecules
  • Mechanism of Action Farnesoid X-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Fibrosis; Non-alcoholic steatohepatitis

Most Recent Events

  • 10 Oct 2017 Preclinical trials in Fibrosis in USA (unspecified route)
  • 10 Oct 2017 Metacrine plans a clinical trial of MET 409 in the first half of 2018
  • 19 Apr 2017 Pharmacodynamics data from a preclinical study of M 480 in Non-alcoholic steatohepatitis presented at the International Liver Congress 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top